Esketamine, administered intravenously or perineurally, appears to lower the risk of rebound pain and improve analgesia without increasing side effects. However, these conclusions are tempered by the limited number of studies and some clinical heterogeneity. Therefore, the current analysis serves more as a working hypothesis generating interest for future large, high-quality trials, which are needed to confirm these results and define optimal dosing strategies before clear clinical recommendations can be made.
ZHONG et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: